Varicella Live Vaccine Market was
valued at $2.71 billion in 2018, and is expected to reach $4.22 billion by
2026, registering a CAGR of 5.7% from 2019 to 2026.
Viral
infections can be prevented by immunization and therefore, immunization is
crucial. Varicella zoster is a virus that causes diseases such as chicken pox
and herpes zoster. However, these infectious diseases can be prevented by the
use of varicella live vaccines. Varicella live vaccines are administered to
both children and adults in a pattern of two doses to ensure complete
immunization. These vaccines contain a weakened form of varicella zoster virus
that is effective in creating immunity against the same virus. There are two
different types of varicella live vaccines such as monovalent and combination
varicella vaccines.
Rise in
immunization programs worldwide is the major factor that boost the growth of
the varicella live vaccine market. In addition, factors such as surge in
awareness related to the use of varicella live vaccines and increase in
adoption of varicella vaccination across the globe fuel the growth of the
varicella live vaccine market. However, high monetary inputs associated with
manufacture of the products restrict the growth of the market. Conversely,
growth potential in emerging economies is expected to create lucrative
opportunities for the market during the forecast period.
Download PDF Report
Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/3969
The global varicella live vaccine market is
segmented based on product, application, and provider. On the basis of product,
the market is bifurcated into monovalent varicella vaccine and combination
varicella vaccine. By application, it is divided into chicken pox immunization,
herpes zoster immunization and measles, mumps, rubella and varicella (MMRV)
immunization.
On the
basis of provider, it is segmented into public provider and private provider.
Based on region, it is analyzed across North America (U.S., Canada, and
Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe),
Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of
Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Based on
product, the monovalent varicella vaccine segment acquired the major share of
the varicella live vaccine market and is expected to experience rapid growth during
the forecast period as these vaccines exhibit lesser chances of inducing
febrile seizures in children as compared to combination vaccines. Moreover,
easy availability and presence of large number of products is another reason
that boosts the growth of the monovalent varicella vaccine market.
Based on
application, chicken pox immunization acquired the largest share of the
varicella live vaccine market owing to vaccination employed with an initial aim
of building immunity against chicken pox. Herpes zoster segment is expected to
grow at the fastest rate during the forecast period owing to surge in geriatric
population worldwide and rise in awareness about the use of varicella live
vaccines for herpes zoster.
On the
basis of region, North America acquired a major share owing to easy
availability of varicella live vaccines, presence of skilled healthcare
experts, and presence of major key players that offer varicella live vaccines.
Asia-Pacific is expected to grow at the fastest rate during the forecast period
due to surge in awareness related to importance of immunization and rise in
disposable income.
The
developing economies offer lucrative opportunities for varicella live vaccine
providers to expand their business. The constantly evolving life science industry
drives the growth of the market in the developing economies such as India,
China, and others.
Key Findings of The Varicella
Live Vaccine Market:
- Monovalent
varicella vaccine occupied two-thirds share of the global varicella live
vaccine market in 2018
- The herpes zoster
segment is anticipated to grow with the highest CAGR throughout the
forecast period
- The private segment
accounted for two-third share of the market in 2018
- Asia-Pacific is
anticipated to grow at the highest rate during the analysis period,
followed by LAMEA
No comments:
Post a Comment